|
목적 : To evaluate the therapeutic effect of subcutaneous adalimumab injection in patients with Behcet’s uveitis with adverse effects of long-term systemic steroid therapy or refractory to systemic steroid therapy.
방법 : We retrospectively reviewed Behcet's uveitis who underwent periodic treatment for more than 3 months using adalimumab. The degree of retinal vasculitis was evaluated by ultra-wide-field fluorescein angiography (FA) using a FA scoring system. Also, the best corrected visual acuity and the degree of anterior chamber cell and vitreous haze were analyzed.
결과 : Forty-four eyes of 23 patients with Behcet’s uveitis were included. At 14 weeks after adalimumab administration, mean FA scores were significantly decreased for optic disc hyperfluorescence (p=0.018), macular edema (p=0.014), retinal vascular staining and/or leakage (p<0.001), capillary leakage (p<0.001) and retinal staining (p<0.001). Anterior chamber cell and vitreous haze grade significantly decreased at both 6 and 14 weeks after adalimumab administration (all p<0.001). The final visual acuity improved by more than two lines on the Snellen chart in 15 eyes (15/44, 34.1%) of 14 patients.
결론 : Adalimumab reduced retinal vascular leakage, anterior chamber cell grade, and vitreous haze grade in Behcet’s uveitis with adverse effects of long-term systemic steroid therapy or refractory to systemic steroids, which were related to the visual improvement.
|